Phenotypic and Molecular Characterization of a Novel blaKPC-202 Variant, Capable of Reverting to blaKPC-2 In Vitro in a Clinical Klebsiella pneumoniae Isolate

In the world of modern medicine, bacteria are constantly evolving, learning to dodge the drugs designed to kill them. One of the most formidable opponents in this invisible war is a type of bacteria called Klebsiella pneumoniae. When this germ develops the ability to resist a powerful class of antibiotics known as carbapenems, it becomes a life-threatening challenge for doctors. To fight back, scientists developed a new weapon: a combination drug called ceftazidime-avibactam. This drug works by pairing an antibiotic with a shield, a molecule that blocks the bacteria's primary defense mechanism, a protein called KPC. For a time, this combination seemed like a guaranteed cure. However, nature is relentless. Bacteria have a remarkable ability to change their shape and structure, sometimes mutating just enough to slip past the shield, rendering the new drug useless. Understanding how these tiny organisms change, and whether those changes can be reversed, is critical for keeping our antibiotics effective.

Researchers at Ruijin Hospital in Shanghai recently uncovered a fascinating and troubling example of this evolutionary flexibility. They studied a specific strain of Klebsiella pneumoniae, named A1518, which was isolated from a patient with a recurring lung infection. This patient had been treated with the ceftazidime-avibactam combination, and while the treatment initially helped, the bacteria returned, now completely resistant to the drug. The medical team set out to understand exactly how this happened. They discovered that the bacteria had not just developed a minor tweak, but had acquired a completely new version of its defense protein, which they named KPC-202. This new variant was capable of breaking down the drug's shield, allowing the bacteria to survive doses that would normally kill it.

To see how this new variant worked, the scientists performed a series of precise experiments. They took the gene responsible for the KPC-202 protein and inserted it into a harmless laboratory strain of bacteria, E. coli. This allowed them to test the protein in isolation, without the other defenses the original patient bacteria possessed. The results were clear: the new protein alone was enough to make the bacteria resistant to ceftazidime-avibactam. However, it did not make them fully resistant to the older carbapenem drugs on its own. The original patient bacteria were resistant to both the new and old drugs because they had two problems at once: the new KPC-202 protein and a separate defect in their outer skin that made it harder for drugs to get inside. The new protein acted as a specialized lockpick for the drug's shield, while the skin defect acted as a barrier, working together to create a super-resistant bug.

The most surprising discovery came when the researchers looked closely at the genetic code of this new KPC-202 variant. They found that the bacteria had inserted a small, extra piece of genetic material into the middle of the gene. This insertion added ten specific building blocks to the protein, creating a new loop in its structure. This extra loop changed the shape of the protein's active center, making it too large for the drug's shield to fit properly. It was like a key that had been slightly widened; it no longer fit the lock, so the shield could not stop the enzyme from destroying the antibiotic. But the story did not end there. The researchers noticed something unusual about how this extra piece of genetic material was arranged. It was a repeating sequence, a tandem repeat, which is known to be unstable.

This instability led to a remarkable observation. When the researchers exposed the bacteria to a different type of antibiotic, meropenem, the bacteria began to change back. The unstable extra piece of genetic material spontaneously fell out of the gene. The bacteria reverted to their original form, the standard KPC-2 protein. Once this happened, the bacteria lost their resistance to ceftazidime-avibactam and became susceptible to it again. However, this reversion came with a cost: the bacteria became more resistant to meropenem. The team calculated that this switch happened frequently enough to be a real concern, occurring in roughly one out of every few hundred thousand bacteria. This demonstrated that the bacteria possessed a genetic switch, allowing them to rapidly adapt to whichever drug was being used. If a doctor switched from the new combination drug to an older one, the bacteria could easily flip this switch, shedding the new resistance and regaining the old one, potentially leading to treatment failure.

The study highlights a complex and dynamic battle between human medicine and bacterial evolution. The researchers identified a novel variant, KPC-202, which emerged under the pressure of ceftazidime-avibactam treatment. They proved that this variant is capable of conferring high-level resistance to the drug. More importantly, they showed that the genetic change responsible for this resistance is reversible. The bacteria can shed the new mutation and return to a previous state when faced with a different antibiotic pressure. This ability to switch back and forth suggests that bacteria are not just slowly changing over years, but can make rapid, precise adjustments to survive immediate threats. The findings serve as a stark reminder that the evolution of resistance is not a one-way street. It is a fluid process where bacteria can adapt, retreat, and adapt again, depending on the environment.

This research underscores the need for careful monitoring of how these bacteria behave. Because the bacteria can hide a resistance trait that only appears under specific conditions, standard tests might miss them. A patient might appear to be cured, only for a hidden subpopulation of bacteria to switch their defenses and cause a relapse. The scientists concluded that doctors and public health officials need to watch for these specific genetic changes and the phenomenon of heteroresistance, where a mix of different bacterial types exists within a single infection. As the medical community continues to develop new drugs, the bacteria will continue to find ways to outmaneuver them. Understanding these mechanisms, from the shape of a single protein to the stability of a genetic sequence, is the only way to stay one step ahead in this enduring struggle.